BIOGY vs. NVZMY
BIOGY (Biogaia AB ADR) and NVZMY (Novozymes AS) are both stocks. BIOGY operates in Drug Manufacturers - Specialty & Generic (Healthcare), while NVZMY operates in Specialty Chemicals (Basic Materials). Over the past 5 years, BIOGY returned -11.48%/yr vs -3.07%/yr for NVZMY. At a 0.01 correlation, their price movements are largely independent.
Performance
BIOGY vs. NVZMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIOGY achieves a 4.09% return, which is significantly higher than NVZMY's -8.20% return.
BIOGY
- 1D
- 0.00%
- 1M
- 4.09%
- YTD
- 4.09%
- 6M
- 10.63%
- 1Y
- 27.47%
- 3Y*
- 9.69%
- 5Y*
- -11.48%
- 10Y*
- —
NVZMY
- 1D
- -0.79%
- 1M
- -7.56%
- YTD
- -8.20%
- 6M
- -4.80%
- 1Y
- -18.14%
- 3Y*
- 7.39%
- 5Y*
- -3.07%
- 10Y*
- 3.31%
BIOGY vs. NVZMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
BIOGY Biogaia AB ADR | 4.09% | 17.64% | 8.00% | 19.28% | -68.47% | -12.12% | 28.87% |
NVZMY Novozymes AS | -8.20% | 14.29% | 3.97% | 12.42% | -38.46% | 46.93% | 4.46% |
Correlation
The correlation between BIOGY and NVZMY is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.02 |
Correlation (5Y) Calculated over the trailing 5-year period | -0.01 |
Correlation (All Time) Calculated using the full available price history since Feb 20, 2020 | 0.01 |
Fundamentals
BIOGY:
$1.11B
NVZMY:
$26.91B
BIOGY:
$3.27
NVZMY:
$1.28
BIOGY:
3.36
NVZMY:
45.11
BIOGY:
0.72
NVZMY:
2.44
BIOGY:
0.80
NVZMY:
2.46
BIOGY:
$1.54B
NVZMY:
$11.07B
BIOGY:
$1.12B
NVZMY:
$5.79B
BIOGY:
$452.36M
NVZMY:
$3.39B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIOGY vs. NVZMY — Risk / Return Rank
BIOGY
NVZMY
BIOGY vs. NVZMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogaia AB ADR (BIOGY) and Novozymes AS (NVZMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIOGY | NVZMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.04 | -0.74 | +1.78 |
Sortino ratioReturn per unit of downside risk | 2.01 | -0.98 | +2.99 |
Omega ratioGain probability vs. loss probability | 1.90 | 0.89 | +1.01 |
Calmar ratioReturn relative to maximum drawdown | 1.89 | -0.57 | +2.46 |
Martin ratioReturn relative to average drawdown | 4.69 | -1.00 | +5.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BIOGY | NVZMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.04 | -0.74 | +1.78 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.26 | -0.11 | -0.15 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.12 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.19 | -0.08 | -0.11 |
Drawdowns
BIOGY vs. NVZMY - Drawdown Comparison
The maximum BIOGY drawdown since its inception was -76.56%, smaller than the maximum NVZMY drawdown of -86.29%. Use the drawdown chart below to compare losses from any high point for BIOGY and NVZMY.
Loading charts...
Drawdown Indicators
| BIOGY | NVZMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -76.56% | -86.29% | +9.73% |
Max Drawdown (1Y)Largest decline over 1 year | -14.57% | -29.64% | +15.07% |
Max Drawdown (3Y)Largest decline over 3 years | -22.60% | -29.64% | +7.04% |
Max Drawdown (5Y)Largest decline over 5 years | -75.17% | -51.86% | -23.31% |
Max Drawdown (10Y)Largest decline over 10 years | — | -51.86% | — |
Current DrawdownCurrent decline from peak | -58.10% | -60.49% | +2.39% |
Average DrawdownAverage peak-to-trough decline | -50.00% | -57.41% | +7.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.86% | 16.95% | -11.09% |
Volatility
BIOGY vs. NVZMY - Volatility Comparison
The current volatility for Biogaia AB ADR (BIOGY) is 4.01%, while Novozymes AS (NVZMY) has a volatility of 7.02%. This indicates that BIOGY experiences smaller price fluctuations and is considered to be less risky than NVZMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIOGY | NVZMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.01% | 7.02% | -3.01% |
Volatility (6M)Calculated over the trailing 6-month period | 7.27% | 16.80% | -9.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.62% | 24.67% | +1.95% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.54% | 27.71% | +15.83% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 48.71% | 27.14% | +21.57% |
Dividends
BIOGY vs. NVZMY - Dividend Comparison
BIOGY's dividend yield for the trailing twelve months is around 3.93%, more than NVZMY's 1.77% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIOGY Biogaia AB ADR | 3.93% | 6.38% | 6.34% | 2.86% | 9.31% | 0.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVZMY Novozymes AS | 1.77% | 1.51% | 1.03% | 2.68% | 1.68% | 0.69% | 0.91% | 1.03% | 1.10% | 1.64% | 0.95% | 0.60% |
Financials
BIOGY vs. NVZMY - Financials Comparison
This section allows you to compare key financial metrics between Biogaia AB ADR and Novozymes AS. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BIOGY vs. NVZMY - Profitability Comparison
BIOGY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Biogaia AB ADR reported a gross profit of 266.78M and revenue of 372.55M. Therefore, the gross margin over that period was 71.6%.
NVZMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported a gross profit of 644.63M and revenue of 1.14B. Therefore, the gross margin over that period was 56.7%.
BIOGY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Biogaia AB ADR reported an operating income of 101.15M and revenue of 372.55M, resulting in an operating margin of 27.2%.
NVZMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported an operating income of 272.81M and revenue of 1.14B, resulting in an operating margin of 24.0%.
BIOGY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Biogaia AB ADR reported a net income of 79.41M and revenue of 372.55M, resulting in a net margin of 21.3%.
NVZMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported a net income of 202.37M and revenue of 1.14B, resulting in a net margin of 17.8%.
Frequently Asked Questions
BIOGY and NVZMY have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVZMY has higher volatility (7.02%) compared to BIOGY (4.01%). In terms of maximum drawdown, BIOGY dropped -76.56% vs NVZMY's -86.29%.
BIOGY currently has the higher Sharpe Ratio (1.04 vs -0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIOGY and NVZMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer